Physician profile
Stephen Eric Clark
NPI 1134122948
$1,806.77
in general payments reported to CMS, 2019-2025
18 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $30.89 · 2021: $44.80 · 2022: $81.44 · 2023: $903 · 2024: $285 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Travel and Lodging: $623 · Entertainment: $61.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.91 |
| Travel and Lodging | $622.90 |
| Entertainment | $61.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $622.90 | 2023 | Da Vinci Surgical System |
| Abbvie INC. | $368.65 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $134.60 | 2024 | Envista Mx60 Iol |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.56 | 2019 | |
| Sight Sciences, INC. | $105.46 | 2023-2025 | Tearcare System, Omni Surgical System |
| Optos, INC. | $61.59 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $44.98 | 2024 | Xdemvy |
| Amgen INC. | $41.55 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $28.38 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $28.05 | 2019-2020 | |
| Biotissue Holdings INC. | $24.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.22 | 2023 | |
| Alcon Vision LLC | $20.27 | 2025 | Eysuvis |
| Dompe US, INC. | $20.08 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $14.52 | 2023 | Cequa |
| Kala Pharmaceuticals, INC. | $14.52 | 2020 | |
| Ocular Therapeutix, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.